Article

Post-vaccination SARS-CoV-2 infections and incidence of the B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center

2021-04-22

Abstract excerpt

<h4>Background</h4> Distribution of mRNA-based SARS-CoV-2 vaccines to healthcare personnel (HCP) in the United States began in December 2020, with efficacy > 90%. However, breakthrough infections in fully vaccinated individuals have been reported. Meanwhile, multiple SARS-CoV-2 variants of concern have emerged worldwide, including the B.1.427/B.1.429 variant first described in California. Little is known about the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2d0ffd3e-6ea9-50cc-89c8-ee73a20e1e3e
DOI: 10.1101/2021.04.14.21255431

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Post-vaccination SARS-CoV-2 infections and incidence of the B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical centerDOI 10.1101/2021.04.14.21255431Read

Post-vaccination SARS-COV-2 among healthcare workers in New Jersey: a genomic epidemiological studySemantic proximity Read

Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineagesSemantic proximity Read

Impact of B.1.351 (beta) SARS-CoV-2 variant on BNT162b2 mRNA vaccine effectiveness in long-term care facilities of eastern France: a retrospective cohort studySemantic proximity Read

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variantsSemantic proximity Read

Prevention of COVID-19 by mRNA-based vaccines within the general population of CaliforniaSemantic proximity Read

SARS-CoV-2 Infections in mRNA Vaccinated Individuals are Biased for Viruses Encoding Spike E484K and Associated with Reduced Infectious Virus Loads that Correlate with Respiratory Antiviral IgG levelsSemantic proximity Read

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5Semantic proximity Read

Immunogenicity and safety of LP.8.1 variant-containing mRNA COVID-19 vaccinesSemantic proximity Read

Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort studySemantic proximity Read

Postvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study.Semantic proximity Read

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity Read

Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trialSemantic proximity Read